EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blood Based Biomarkers for Predicting Treatment Response to Immune Checkpoint Inhibitors After EGFR ‐ TKI Resistance in Non‐Small Cell Lung Cancer

Min Seok Park, Jun Hyeok Lim iD, Nuri Park, Eunji Park, Ayoung Lim, Suji Lee, Yejin Cho, Sehan Kwak, Minseo Lee, Donghyun Seo, Lucia Kim, Woo Kyung Ryu und 4 weitere

Thoracic Cancer · 2026-03 · 17 (6)

DOI: 10.1111/1759-7714.70257 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 13.03.2026. Verfasst von Min Seok Park und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, College of Medicine, Inha University, Incheon, Republic of Korea. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Immune Checkpoint Inhibitors, Tyrosine Kinase Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korean Association for the Study of Targeted Therapy, National Research Foundation of Korea (NRF), Inha University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have limited benefit in epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC). However, they are often tried after tumors develop resistance to EGFR tyrosine kinase inhibitors (TKIs). Because EGFR‐TKI treatment alters the tumor microenvironment, biomarkers predictive of ICI response are ideally identified post‐EGFR‐TKI resistance, but obtaining repeat biopsies at this time can be challenging. The purpose of this study was to explore predictive biomarkers for ICI response using plasma samples collected after EGFR‐TKI therapy.

Methods

This retrospective analysis included 28 patients with EGFR‐mutant NSCLC treated with an ICI after developing resistance to EGFR‐TKI. Plasma samples collected at TKI progression were profiled using an Olink Target 96 immune protein panel to identify differential protein expression. Candidate protein biomarkers were validated by immunohistochemistry in tumor tissue. Durable clinical response (DCB) was defined as patients achieving progression‐free survival (PFS) ≥ 6 months during ICI therapy.

Results

Of the 28 patients, 6 (21.4%) achieved durable clinical benefit, with PFS ≥ 6 months. Proteomic analysis identified four plasma proteins that differed significantly between DCB and NCB. Gal‐9 and GZMH levels were elevated in NCB, whereas IL‐4 and IL‐6 were elevated in DCB. Notably, PFS was significantly longer in patients with lower Gal‐9 and higher IL‐4 levels.

Conclusions

Plasma‐based immune markers measured at the time of TKI resistance may help predict which patients with EGFR‐mutant NSCLC will respond to subsequent ICI therapy. Such biomarkers could guide immunotherapy decision‐making in this clinically challenging population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorImmune Checkpoint InhibitorsTyrosine Kinase InhibitorsLung NeoplasmsCarcinoma, Non-Small-Cell LungDrug Resistance, NeoplasmRetrospective StudiesErbB ReceptorsProgression-Free SurvivalPrognosisPredictive Value of TestsDisease ProgressionHumansMaleFemaleMiddle AgedAgedMutation

Stichwörter der Autor:innen

epidermal growth factor receptorimmune checkpoint inhibitorliquid biopsynon‐small cell lung cancerpredictive biomarkertreatment responsetyrosine kinase inhibitor

Substanzen

Biomarkers, TumorImmune Checkpoint InhibitorsEGFR protein, humanErbB ReceptorsTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Biomedical Sciences, College of Medicine, Inha University, Incheon, Republic of Korea.
  • Division of Pulmonology, Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea.
  • Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Medicine, Inha University College of Medicine, Incheon, Republic of Korea.
  • Department of Pathology, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea.
  • Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Jun Hyeok Lim

Förderung

  • Korean Association for the Study of Targeted Therapy
  • National Research Foundation of Korea (NRF)
  • Inha University

Zitieren

APA

Park, M. S., Lim, J. H., Park, N., Park, E., Lim, A., Lee, S., Cho, Y., Kwak, S., Lee, M., Seo, D., Kim, L., Ryu, W. K., Ryu, J. S., Kim, E. Y., Hong, S. S., & Jung, K. H. (2026). Blood Based Biomarkers for Predicting Treatment Response to Immune Checkpoint Inhibitors After EGFR ‐ TKI Resistance in Non‐Small Cell Lung Cancer. Thoracic Cancer, 17(6). https://doi.org/10.1111/1759-7714.70257

Vancouver

Park MS, Lim JH, Park N, Park E, Lim A, Lee S, et al. Blood Based Biomarkers for Predicting Treatment Response to Immune Checkpoint Inhibitors After EGFR ‐ TKI Resistance in Non‐Small Cell Lung Cancer. Thoracic Cancer. 2026;17(6). doi:10.1111/1759-7714.70257

BibTeX
@article{Park2026,
  author = {Park, Min Seok and Lim, Jun Hyeok and Park, Nuri and Park, Eunji and Lim, Ayoung and Lee, Suji and Cho, Yejin and Kwak, Sehan and Lee, Minseo and Seo, Donghyun and Kim, Lucia and Ryu, Woo Kyung and Ryu, Jeong-Seon and Kim, Eun Young and Hong, Soon-Sun and Jung, Kyung Hee},
  title = {Blood Based Biomarkers for Predicting Treatment Response to Immune Checkpoint Inhibitors After EGFR ‐ TKI Resistance in Non‐Small Cell Lung Cancer},
  journal = {Thoracic Cancer},
  year = {2026},
  volume = {17},
  number = {6},
  doi = {10.1111/1759-7714.70257}
}
Kostenlos starten →